Amylyx Pharmaceuticals, Inc. (AMLX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-24

Key Insights

Amylyx Pharmaceuticals has completed enrollment in the Phase 3 LUCIDITY trial, a key milestone in the development of its lead drug candidate.
The company has added new exploratory analysis from the Phase 2 PREVENT study to its corporate presentation, potentially providing additional insights into the product's efficacy.
Amylyx has also completed enrollment for Cohort 2 in the Phase 1 LUMINA trial, further advancing its pipeline.

Want the newest filings?

This analysis covers the filing from 2026-03-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-08

Amylyx Pharmaceuticals has selected a new development candidate, AMX0318, a long-acting GLP-1 receptor antagonist, for the treatment of post-bariatric hypoglycemia and other rare diseases.
The selection of AMX0318 triggers milestone payments of $4 million to Gubra, Amylyx's research partner, under the terms of their collaboration agreement.
Amylyx has updated its corporate presentation for investor meetings, providing insight into the company's pipeline and development plans.

Other reports for Amylyx Pharmaceuticals, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.